Hormonal
Pharmacotherapies for T2D and obesity, specifically GLP-1 receptor agonists (e.g., Tirzepatide) and SGLT2 inhibitors, cause significant loss of lean body mass (20-50% of total weight loss), necessitating concurrent resistance exercise and protein intake to mitigate muscle loss.
If you are taking GLP-1 or SGLT2 medications for diabetes or weight loss, expect to lose some muscle along with fat (up to 50% of the weight). To protect your metabolism and strength, you must combine these medications with resistance exercise and adequate protein intake, as the drugs themselves do not preserve muscle.
a large proportion (20–50%) of the weight loss comes from lean mass, indicative of a loss in muscle mass.
Why this rating
Supported by recent reviews of clinical trials (SURMOUNT-1, etc.).
Source
Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?
Amina Al-Awadi et al. · Reviews in Endocrine and Metabolic Disorders · 2025
DOI 10.1007/s11154-025-09947-8
More from this paper
- Resistance exercise is the most effective lifestyle intervention for increasing muscle strength in people with type 2 diabetes (T2D), although it may induce an anabolic resistance regarding muscle mass gains compared to healthy controls.Good
- Increasing dietary protein intake alone does not overcome anabolic resistance in T2D, but protein supplementation combined with resistance exercise may improve lean mass gains compared to exercise alone.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →